Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:IMRX NASDAQ:NMRA NASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$7.90$9.85$3.92▼$19.15$71.18M0.0874,049 shs75,238 shsIMRXImmuneering$4.32$4.75$2.90▼$10.08$279.50M0.41943,569 shs465,240 shsNMRANeumora Therapeutics$1.49$1.65$0.83▼$3.65$276.07M2.74875,332 shs665,727 shsORICOric Pharmaceuticals$12.10$9.39$7.23▼$14.93$1.25B1.021.56 million shs3.61 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-5.84%-24.83%+58.32%-31.78%IMRXImmuneering0.00%-6.90%-9.07%-25.00%+6.40%NMRANeumora Therapeutics0.00%-7.45%-9.15%-32.88%-36.60%ORICOric Pharmaceuticals0.00%+12.77%+26.97%+18.74%+5.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$7.90$9.85$3.92▼$19.15$71.18M0.0874,049 shs75,238 shsIMRXImmuneering$4.32$4.75$2.90▼$10.08$279.50M0.41943,569 shs465,240 shsNMRANeumora Therapeutics$1.49$1.65$0.83▼$3.65$276.07M2.74875,332 shs665,727 shsORICOric Pharmaceuticals$12.10$9.39$7.23▼$14.93$1.25B1.021.56 million shs3.61 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-5.84%-24.83%+58.32%-31.78%IMRXImmuneering0.00%-6.90%-9.07%-25.00%+6.40%NMRANeumora Therapeutics0.00%-7.45%-9.15%-32.88%-36.60%ORICOric Pharmaceuticals0.00%+12.77%+26.97%+18.74%+5.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.5020.25% UpsideIMRXImmuneering 2.86Moderate Buy$17.57306.75% UpsideNMRANeumora Therapeutics 2.60Moderate Buy$6.57341.04% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2759.28% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ORIC, IMRX, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026IMRXImmuneering Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $18.007/17/2026NMRANeumora Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026NMRANeumora Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.006/24/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026NMRANeumora Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $4.006/16/2026NMRANeumora Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $7.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.59$4.88 per share1.62($5.34) per share-1.48IMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.62 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M-$0.67N/A5.64N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)Latest ATRA, ORIC, IMRX, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026IMRXImmuneering-$0.26N/AN/AN/AN/AN/A8/11/2026Q2 2026ORICOric Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/10/2026Q2 2026ATRAAtara Biotherapeutics-$0.3150N/AN/AN/A$0.55 millionN/A8/5/2026Q2 2026NMRANeumora Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A2.162.16IMRXImmuneeringN/A32.4532.45NMRANeumora Therapeutics0.755.095.09ORICOric PharmaceuticalsN/A16.3316.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%IMRXImmuneering67.65%NMRANeumora Therapeutics47.65%ORICOric Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%IMRXImmuneering22.90%NMRANeumora Therapeutics26.94%ORICOric Pharmaceuticals5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataIMRXImmuneering6064.70 million49.88 millionNot OptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableATRA, ORIC, IMRX, and NMRA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Oric Pharmaceuticals (NASDAQ:ORIC) to SellJuly 25 at 1:37 AM | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street ZenJuly 25 at 1:35 AM | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4% - Time to Buy?July 24 at 12:59 PM | marketbeat.comSiren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORICJuly 24 at 6:25 AM | marketbeat.comORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull CaseJuly 21, 2026 | seekingalpha.comORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026July 20, 2026 | globenewswire.comORIC Pharmaceuticals Inc 4TZJuly 16, 2026 | morningstar.comMOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Moderate Buy" by AnalystsJuly 16, 2026 | americanbankingnews.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 16, 2026 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Here's What HappenedJuly 15, 2026 | marketbeat.comORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical ...July 15, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with BayerJuly 14, 2026 | globenewswire.comCandriam S.C.A. Buys Shares of 574,085 Oric Pharmaceuticals, Inc. $ORICJuly 13, 2026 | marketbeat.comY Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORICJuly 11, 2026 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comORIC gains as Stifel resumes at buy on upcoming Pfizer readoutJune 13, 2026 | msn.comORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comORIC Pharmaceuticals Inc ORICMay 31, 2026 | morningstar.comMORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 21, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026PepsiCo’s Dividend Could Turn Patience Into Real ProfitBy Thomas Hughes | July 10, 2026ATRA, ORIC, IMRX, and NMRA Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$7.90 0.00 (0.00%) As of 07/24/2026 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Immuneering NASDAQ:IMRX$4.32 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$1.49 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.49 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Oric Pharmaceuticals NASDAQ:ORIC$12.10 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.14 +0.04 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
